NB100-64980 recognizes a heparan sulfate rich membrane glycoprotein of 200kD known as Syndecan-1 (CD138). Syndecan functions as a receptor for collagen, fibronectin and thrombospondin. NB100-64980 stains all plasma cells and plasma cell lines. No staining of other leucocytes is seen in peripheral blood or bone marrow, although some ALL cell lines express the antigen weakly. Some staining of epithelial and endothelial cells may be seen in immunohistology.
Protein G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
For Flow Cytometry: Use 10 ul of the suggested working dilution to label 10^6 cells in 100 ul. For IHC: This product requires heat pre-treatment. Sodium citrate buffer pH 6.0 is recommended for this purpose.
CD138 / Syndecan 1 is a transmembrane heparin sulphate proteoglycan which is made up of one core protein and five glycosaminoglycan. CD138 is expected to play a role in cell adhesion. It is expressed on the surface of pre B cells and plasma cells but is absent from mature B cells. It is a selective marker for B cell lymphoblastic leukemia and lymphoplasmocytoid leukemia. It is lost from the apoptotic myeloma cells; hence is a useful marker for viable myeloma cells. This antibody stains all plasma cells and plasma cell lines. No staining of other leucocytes is seen in peripheral blood or bone marrow, although some ALL cell lines express the antigen weakly. Some staining of epithelial and endothelial cells may be seen in immunohistology.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
FAQs for Syndecan-1/CD138 Antibody (NB100-64980). (Showing 1 - 2 of 2 FAQs).
Does this product work on endometrial tissue?
Syndecan-1/CD138 antibody (NB100-64980) is a great antibody and it should work in any sections as long as they have CD138 antigen. As far as endometrial tissue is concerned, I am assuming that the cancerous endometrial tissue express Syndecan-1/CD138 while the normal tissue does not express it that much. And we would suggest the customer to include a positive control section in the assay using any of the following tissues: Normal Tissues:- Placenta, Colon, Small Intestine or Tonsil; Cancerous Tissues:- Ovarian cancer, rectal cancer, Lung cancer.
Is this differ from anti human syndecan-1 mouse B-B4 monoclonal antibody?
Our NB100-64980 is Syndecan-1/CD138 antibody’s clone B-A38 and this clone is similar to clone B-B4. Both of these clones are IgG1 monoclonal antibodies generated in mouse using U266 myeloma cell line as immunogen. Both of these clones recognize CD138 antigen/ Syndecan-1 protein selectively on Plasma cells /B Cells and are routinely utilized for the diagnosis of multiple myeloma. We do not have license to sell Clone B-B4 at the moment, therefore, the customer can buy our Syndecan-1/CD138 antibody (clone B-A38) NB100-64980 which is a similar product by nature and performance in immunoassays.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Syndecan-1/CD138 Antibody (B-A38) and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.